Mark Stafford-Smith, MD, CM, FRCPC

• Professor of Anesthesiology
• Director of Fellowship Education
• Director of Cardiothoracic Anesthesia and Critical Care
• Medicine Fellowship
• Division of Cardiothoracic Anesthesia and Critical Care Medicine
• Department of Anesthesiology
• Duke University Medical Center
• Durham, North Carolina

Steveling pain management for dogs with hip dysplasia buy motrin 600 mg cheap, Esther Helen valley pain treatment center az discount motrin uk, Mongkol Lao-Araya chronic back pain treatment guidelines motrin 600 mg free shipping, Christopher Koulias pain management for dog in heat buy motrin overnight delivery, Guy Scadding pain diagnosis treatment center tulsa effective 600 mg motrin, Aarif Eifan, Louisa K. Stokes, Andrea B, Elisabeth Kieninger, Aline Schögler, Brigitte S Kopf, Carmen Casaulta, Thomas Geiser, Nicolas Regamey, and Marco P Alves. Sugasawa, Yusuke, Keisuke Yamaguchi, Seiichiro Kumakura, Taisuke Murakami, Toyoki Kugimiya, Kenji Suzuki, Isao Nagaoka, and Eiichi Inada. Sugasawa, Yusuke, Keisuke Yamaguchi, Seiichiro Kumakura, Taisuke Murakami, Kenji Suzuki, Isao Nagaoka, and Eiichi Inada. Yamazaki, Koichi, Shigeaki Ogura, Akitoshi Ishizaka, Toshinari Oh-hara, and Masaharu Nishimura. Yasuda, Hiroyuki, Kenzo Soejima, Sohei Nakayama, Ichiro Kawada, Ichiro Nakachi, Satoshi Yoda, Ryosuke Satomi et al. Watanabe, Masazumi, Akitoshi Ishizaka, Eiji Ikeda, Akira Ohashi, and Koichi Kobayashi. Woodruff, Prescott G, Homer A Boushey, Gregory M Dolganov, Chris S Barker, Yee Hwa Yang, Samantha Donnelly, Almut Ellwanger et al. As a result, we have also witnessed the development of a large number of novel therapeutic agents (both biologics and small molecules) across a broad spectrum of autoimmune conditions. Although many drugs have been successful, there is very little evidence to demonstrate clear superiority of one drug over another. At an individual patient level it remains unclear which drug is most likely to elicit an excellent response/remission. Current therapeutic decision making is therefore driven largely by order of entry to the market, drug pricing and national approval processes. There is a pressing need for a better evidence base to inform therapeutic choices (Isaacs and Ferraccioli 2011). Biosimilars are now entering the marketplace meaning that the choice of individual agent for any patient at any stage of their disease is much greater than previously (Nam et al. There is also very little evidence of any clear superiority in efficacy of one drug over the other in "all-comer" trials of these agents (Weinblatt et al. A subsequent systematic review suggested, however, that despite a number of studies showing similar results, the effect size was small and may therefore not have any clinical utility in decision making (Cuppen et al. Overall limitations of these genetic studies to date have been small numbers in many cohorts and lack of a confirmation set. In addition, a number of findings have not been assessed in other drugs exposures, for example, the work by Viatte et al. Although synovial biopsies can only be performed by trained operators, the synovium offers an attractive ad highly relevant tissue to sample for the purpose of identifying predictive biomarkers. Infliximab responders had significant up-regulation of immune-related pathways including those involved in cytokine signaling and cell adhesion. In addition to being a biomarker of those more likely to respond, Genetic Markers A number of studies have also examined whether genetic polymorphisms associated with disease susceptibility or severity may also act as predictors of response to therapeutic agents. Understandably, the use of synovial biopsy has not yet entered routine clinical practice due to at least, in part, it being an invasive procedure requiring expert operators. The natural progression is therefore to try to extrapolate biopsy findings to other more readily available biofluids. Cellular and Cytokine Biomarkers Cellular biomarkers may also offer some predictive value and modify the effects of some of the serum biomarkers although results have been conflicting. Plasmablasts are a distinct subtype of plasma cells that secrete large quantities of immunoglobulin. Although much effort has been made to identify serum cytokine biomarkers to predict response, there has been little success. Importantly, this signature can be modified by the use of corticosteroids (de Jong et al. This has the undesirable effect of reducing the predictive value of using the signature to predict response in patients also taking steroids. Clinical features include a wide spectrum of manifestations including joint pain, rashes, photosensitivity and alopecia but also deeper organ involvement including serositis, renal involvement (lupus nephritis), hematological disorders including hemolytic anemia, and central nervous system involvement. The therapeutic paradigm for lupus broadly addresses the extent and severity of disease manifestations. Early therapy will include symptomatic therapy and antimalarial drugs particularly hydroxychloroquine. Low dose steroids are often used to control symptoms in patients with mild/ moderate disease. Although there is clinical trial evidence to support the efficacy of a number of these drugs, it is important to note that apart from antimalarial drugs and corticosteroids (broadly approved for inflammatory disorders) none of the usual classic immunosuppressant therapies used in lupus have are licensed for this condition. For extra-renal disease a wide variety of potential clinically active manifestations may contribute to the disease activity score that gets the patient in to the trial. Therefore, although the majority enter a trial with mucocutaneous and/or articular disease (Navarra et al. Whether this classic separation, or stratification, of patient groups for clinical trials is the correct approach for the future is a matter of considerable debate. At a genetic level there has been enormous increase in our understanding of the genetic susceptibility of lupus and related conditions. It should be noted that there is a wide degree of overlap in genetic susceptibility markers between a number of these related conditions. Although these point to common immunological pathways of relevance in the pathogenesis of lupus, it also suggests subsets of patients where particular targeted therapies may be more likely to succeed. This heterogeneity might of course also explain why trials to date have been unsuccessful. Recent elucidation of monogenic forms of lupus also suggest that certain distinct pathways may have a particular strong drive toward the pathogenesis and development of lupus (Crow and Manel 2015; An et al. In patients with moderate to severe lupus approximately 70%­80% of active patients had a high interferon gene signature. Even in this group, however, there was a bimodal pattern where 20%­30% did not have a high signature. In milder disease the bimodal pattern was also demonstrated and the population was approximately 50:50 with regard to elevated interferon gene transcripts (Kalunian et al. More recently, in a longitudinal analysis of transcript only profiling of whole blood of patients with paediatric onset lupus, within this population there were seven subset or "strata" of patients identified (Banchereau et al. In addition to a prevalent interferon signature, there was strong evidence of a plasmablast signature being associated with disease activity. In addition, neutrophil transcripts appeared associated with progression to active lupus nephritis and several other signatures appeared to correlate with response to specific therapy (Banchereau et al. Other autoantibodies that seem to relate to specific manifestations such as lupus nephritis; for example, anti-C1q antibodies occur in approximately a quarter of patients with lupus (Orbai et al. In inflammatory myopathies, a wide spectrum of myositis specific antibodies has been described with very little overlap but which seem to track with particular clinical manifestations (Betteridge and McHugh 2016). In addition, the autoantibody profile of most patients will have been known to the physician at the time of deciding on new therapies. Several studies have sought to address how these biomarkers relate to response to therapy. Pharmacodynamic Changes A dynamic immunological environment exists following B-cell targeted therapies (Vital et al. Several agents have been developed to specifically target this pathway including rontalizumab, sifalimumab and anafrolimab. Pharmacodynamically, this drug inhibits the type 1 interferon gene signature (Higgs et al. In addition, this population also had a higher risk of leukopenia and gastrointestinal adverse (Shu et al. In a number of studies with patients undergoing renal transplant these enzymes have relevance in levels of immunosuppression and adverse events seen. There was a higher rate of achieving the primary end point in patients taking anifrolumab compared with placebo. When patients were stratified by their interferon signature at baseline patients with a high baseline interferon signature had a greater effect size on drug compared with placebo (again this was because of a lower placebo response in this population 13. This group also had less clinical flares over the period of follow up (Kalunian et al. Similarly, outcome measures used in other conditions such as skin thickening scores in systemic sclerosis (Clements et al. In these settings, it may be difficult therefore to distinguish true clinically meaningful biological effect. In both contexts however we are beginning to learn important lessons about disease heterogeneity and potential biomarker that may help to better stratify populations for more targetted therapies. In Press) In both cases only a limited number of studies could be assessed and many of these were post hoc and secondary analyses and as such carried a high risk of bias based on the lack of adjustment for additional confounding variables etc. There was also evidence that some of the factors that were associated with response in general rather than being drug specific (Mendoza-Pinto et al. The metric properties of the clinical outcome measures can restrict their ability to fully address the biology of disease particularly in situations where a differential effect or a substrata of patients is being studied. The scoring system demands that the skin rash has to be completely cleared before any reduction in the score for that item changing. Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. Personalized Immunomonitoring Uncovers Molecular Networks That Stratify Lupus Patients. The Development of GenomeWide Association Studies and Their Application to Complex Diseases, Including Lupus. Myositis-Specific Autoantibodies: An Important Tool to Support Diagnosis of Myositis. Progress in Understanding the Diagnostic and Pathogenic Role of Autoantibodies Associated with Systemic Sclerosis. Skin Thickness Score in Systemic Sclerosis: An Assessment of Interobserver Variability in 3 Independent Studies. Personalized Biological Treatment for Rheumatoid Arthritis: A Systematic Review with a Focus on Clinical Applicability. A Multi-Parameter Response Prediction Model for Rituximab in Rheumatoid Arthritis. Effect of Prednisone on Type I Interferon Signature in Rheumatoid Arthritis: Consequences for Response Prediction to Rituximab. Anifrolumab, an AntiInterferon- Receptor Monoclonal Antibody, in Moderate-toSevere Systemic Lupus Erythematosus. The Relationship between Synovial Lymphocyte Aggregates and the Clinical Response to Infliximab in Rheumatoid Arthritis: A Prospective Study. Can We Identify Who Gets Benefit or Harm from Mycophenolate Mofetil in Systemic Lupus Erythematosus Mortality Trends in Patients with Early Rheumatoid Arthritis over 20 Years: Results from the Norfolk Arthritis Register. Autoantibodies in Systemic Lupus Erythematosus: Comparison of Historical and Current Assessment of Seropositivity. Effects of Uridine Diphosphate Glucuronosyltransferase 2B7 and 1A7 Pharmacogenomics and Patient Clinical Parameters on Steady-State Mycophenolic Acid Pharmacokinetics in Glomerulonephritis. Sifalimumab, an Anti-Interferon- Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus: A Randomised, Double-Blind, Placebo-Controlled Study. Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised, Placebo-Controlled, Phase 3 Trial. The Influence of Age at Symptom Onset and Length of Followup on Mortality in Patients with Recent-Onset Inflammatory Polyarthritis. B Cell Depletion Therapy in Systemic Lupus Erythematosus: Long-Term Follow-up and Predictors of Response. Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, DoseEscalation Study. Methotrexate as the "Anchor drug" for the Treatment of Early Rheumatoid Arthritis. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus. Efficacy and Safety of Rituximab in Patients with Active Proliferative Lupus Nephritis: the Lupus Nephritis Assessment with Rituximab Study. A Combination of Cellular Biomarkers Predicts Failure to Respond to Rituximab in Rheumatoid Arthritis: A 24-Week Observational Study. Baseline Tumour Necrosis Factor Alpha Levels Predict the Necessity for Dose Escalation of Infliximab Therapy in Patients with Rheumatoid Arthritis. Combination of B Cell Biomarkers as Independent Predictors of Response in Patients with Rheumatoid Arthritis Treated with Rituximab. Responsiveness to Anti-Tumour Necrosis Factor Alpha Therapy Is Related to Pre-Treatment Tissue Inflammation Levels in Rheumatoid Arthritis Patients. Belimumab in the Treatment of Systemic Lupus Erythematosus: High Disease Activity Predictors of Response. The Clinical Response to Infliximab in Rheumatoid Arthritis Is in Part Dependent on Pretreatment Tumour Necrosis Factor Alpha Expression in the Synovium. The Use of Systemic Lupus Erythematosus Disease Activity Index-2000 to Define Active Disease and Minimal Clinically Meaningful Change. Brief Report: Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus. Pharmacological Induction of Interferon Type I Activity Following Treatment with Rituximab Determines Clinical Response in Rheumatoid Arthritis. It cannot be overemphasized that the lupus diagnostic criteria were developed to identify patients suitable for clinical trials, and that strict adherence to the criteria may not allow us to thoroughly capture patients who would benefit from lupus-directed interventions.

Moreover ankle pain treatment physiotherapy 600 mg motrin order mastercard, the combination of whole exome sequencing and glycomics will be essential for an optimal diagnostic result cape fear pain treatment center lumberton nc order motrin mastercard. Since their first description in 1980 pain home treatment purchase motrin cheap, more than 100 different defects have been identified sciatica pain treatment guidelines discount motrin 400 mg with visa. In addition acute chest pain treatment guidelines cheap motrin 400 mg with mastercard, an increasing number of genetic defects are being identified that result in abnormalities in multiple pathways. Protein-specific glycoprofiling has a couple of advantages over the more generally applied total serum glycomics. This broad reference range became evident with the recent publication of Hennig and coworkers, where they show that healthy individuals present with large variations in their glycosylation phenotype (Hennig et al. Likely, the glycome reflects the genetic, epigenetic and metabolic system, influenced by individual lifestyles and environmental factors, leading to large interindividual glycome heterogeneity. Importantly, within one individual, changes in glycosylation are rather small over time (Hennig et al. In clinical diagnostics, commonly a one-time sampling is performed, which is not always adequate to show the genetic defect. For precision medicine, however, the glycome might be a highly sensitive marker given that changes within one individual are small. Initial studies are highly promising to mediate novel early diagnosis and disease stratification markers, subsequently resulting in improved patient well-being and reduced treatment costs (Almeida and Kolarich 2016). In addition, for therapy monitoring, which will be discussed in the next paragraph, glycomics is a highly sensitive and fast approach to optimize the treatment of the individual patient. The three most commonly applied techniques used to analyze biological fluid were presented here. There are a few approaches that are currently considered: chaperone therapy, enzyme replacement therapy 398 Handbook of Biomarkers and Precision Medicine branching, and truncation of O-glycans, which impact important cancer-associated processes like proliferation, invasion, metastasis, and angiogenesis. Changes in glycosylation can influence cancer progression (Pinho and Reis 2015, Taniguchi and Kizuka 2015) and treatment response in multiple ways (Park et al. Identifying the glycosylation changes and understanding underlying mechanisms has, therefore, vast potential in the development of novel biomarkers for diagnosis, stratification, and prognosis. Likewise, new therapies are emerging that intervene with cancer-related, glycan-mediated processes, including novel immunotherapeutics (Hudak and Bertozzi 2014, Vankemmelbeke et al. Intact transferrin glycoprofiling has been applied successfully to monitor the biochemical improvement during galactose supplementation: a good example of how glycoprofiling can be used to monitor disease severity and treatment efficacy (Tegtmeyer et al. Glycomics for Improved Cancer Diagnostics As mentioned in the introduction, various glycoproteins and glycolipids have already been routinely used and measured in clinics for a long period. Recent studies have shown that including information on the glycosylation of the glycoconjugates provide important insights and could increase sensitivity and/or specificity for diagnosis and prognosis. Another study found up to hexa-fucosylated N-glycans on haptoglobin in hepatocellular carcinoma, whereas N-glycans on haptoglobin from controls contained only one or none fucose (Pompach et al. Tumor initiation is thought to be caused by genetic alterations of a single cell that will proliferate and develop to a cell population (Marusyk and Polyak 2010). During tumor progression, more mutations accumulate that influence cellular processes giving advantage to the cancer cells. However, genetic alterations are not the only players in cancer development and other nongenetic factors contribute to a large intra-tumor heterogeneity and complex tumor biology (Caiado et al. Several glycosylation changes have been reported and reviewed (Pinho and Reis 2015, Kailemia et al. Strikingly, in gastric cancer the specific glycosylation site at Asn-554 seems to be the major player in this progress (Carvalho et al. Furthermore, the nonhuman sialic acid, N-glycolylneuraminic acid (NeuGc), has gained a lot of attention, especially for cancer vaccines (Vazquez et al. For patients with high intake of NeuGc-containing dietary products, novel anti-NeuGc antibodies might be a promising tailored treatment or drug delivery approach because NeuGc is especially enriched in cancer tissues. Polymorphisms in the glycosylation pathway can alter the receptor glycosylation and, therefore, result in different drug responses and efficacies between patients (Lauc et al. Taking these results into account, levels of sialylation might be a good personalized indicator for the prediction of treatment responses. Histo-blood group antigens, for example, are glycan epitopes and result from individual genetic polymorphisms in glycosyltransferase genes. Their potential in precision medicine has been recently reviewed by Dotz and Wuhrer (2015). The risk for viral and bacterial infections, for example, may depend on the secretor status (Underwood et al. Moreover, antibody glycosylation associates with disease activity and progression in rheumatoid arthritis (Mesko et al. Disease control has always been hampered by a lack of tools, including rapid, point-of-care diagnostics, but in their study, they showed that Fc-effector functions are distinct between these two groups of tuberculosis patients and highlighted that antibodies from latent patients can activate antimicrobial responses more effectively than antibodies from patients with active infections. Robust and sensitive high-throughput screenings of large sample sets enable population-based cross-sectional as well as longitudinal studies and have already resulted in the characterization of cancer- and other disease-associated glycans changes, revealing potential novel biomarkers (Lauc et al. A recent longitudinal study has shown that the serum glycan profile of an individual is rather stable over a longer period of time. It changes, however, significantly with inflammation and various diseases (Hennig et al. It might well be that the individual glycome reflects the risk for certain diseases, disease course and the response to therapy. To prove these hypotheses, large cohort studies need a layer of biological information to explain the large variations between individuals (Lauc et al. Although these high-throughput screening methods are mainly applied on released glycans often from serum, plasma or other biofluids, protein-specific or site-specific glycosylation changes are less amenable to high-throughput analysis, but instead unravel important biological information and can improve diagnostic and prognostic performance through better sensitivity and specificity, as discussed earlier. The advantage of site-specific analysis is the detection of subtle glycosylation differences, but it remains the analytically most challenging approach. In summary, further developments for the measurement of extremely small sample amounts as well as absolute quantification and robust platforms that easily transfer to the clinics are the subject of ongoing research. With regard to the complexity of glycosylation as a cellular process, the different factors involved in this process as well as the non­template-driven biosynthesis, it remains challenging to identify regulatory and causal events as well as the direct functional relevance for the disease (Almeida and Kolarich 2016). Consequently, novel bioinformatics and systems biology tools are urgently needed to integrate different data sets, considering the potential relationships between the different players (Bennun et al. To conclude, glycomics provides a novel discipline with unprecedented density of biological information. This is exactly why this approach is so promising for clinical research, especially in the context of personalized medicine. Ongoing technological advances facilitate the analysis of complex glycosylation and need to make their way into routine clinical applications. Solving glycosylation disorders: Fundamental approaches reveal complicated pathways. Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. Towards personalized diagnostics via longitudinal study of the human plasma N-glycome. Systems glycobiology: Integrating glycogenomics, glycoproteomics, glycomics, and other omics data sets to characterize cellular glycosylation processes. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. The role of N-glycans in colorectal cancer progression: Potential biomarkers and therapeutic applications. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. A method for In-Depth structural annotation of human serum glycans that yields biological variations. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Human milk oligosaccharides in premature infants: Absorption, excretion, and influence on the intestinal microbiota. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. Racotumomab: an anti-idiotype vaccine related to N-glycolylcontaining gangliosides-preclinical and clinical data. Derivatization of sialic acids for stabilization in matrix-assisted laser desorption/ ionization mass spectrometry and concomitant differentiation of alpha(2 -> 3)- and alpha(2 -> 6)-isomers. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. A novel N-tetrasaccharide in patients with congenital disorders of glycosylation, including asparagine-linked glycosylation protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies. This dynamic regulation has unveiled them as critical regulators of a wide range of cellular events. Therefore, their deregulation is frequently associated with disease triggering and development. However, this degradation process is different and involves recruitment of deadenylase complexes that remove or shorten the poly-A tail of the target transcript. However, this slow turnover is not suitable for their capacity to regulate rapid cell responses to environmental signals in other contexts. Their presence in a peripheral fluid allows diagnosis by minimum invasive methods because samples can be easily and routinely obtained in clinical practice. Not all the blood markers are so stable, thus affecting the tests reproducibility. Most of them are secreted at the initial steps of the pathophysiological mechanisms responsible for diseases. Moreover, because they are fine-tuned regulators and orchestrate continuous cell response to stimuli, they bring a dynamic knowledge of the pathology evolution. Targeted Proteomics for Absolute Quantification of Protein Biomarkers in Serum and Tissues 7. In these biological processes, molecular and chemical interactions between proteins form the basis of health and disease [1]. Moreover, proteins by themselves are complex biomolecules that do not exist mostly as single structures. Different modifications such as phosphorylation can exist but also, for instance, differences in the primary, secondary structure of proteins. The different individual protein structures can be well studied regarding their functions; however, the high diversity of modifications of a protein makes it hard to implement the full understanding of how it relates to molecular mechanisms in health and disease. In other words, a certain protein biomarker in a body fluid does not depict its importance per se given that it is likely present in different isoforms. Advantages of the immunoassay technology are the high selectivity and sensitivity. However, immunoassays have limitations such as the high development cost for sensitive and well-characterized antibodies as well as cross-reactivity with other proteins or interference from other ligands bound to the target protein [4]. Mostly, the primary structure of the antibody is not available and, therefore, the antibody delivered is a kind of black box [5]. Most importantly, the often-limited specificity of the antibodies that are key components of immunoassays limit their use in biomarker analysis, which requires optimal specificity in addition to sensitivity. The various proteomics methods can roughly be classified in bottom-up proteomics (focusing on identification of protein fragments following proteolytic digestion), top-down proteomics (focusing on intact proteins) and targeted proteomics (focusing on quantifying preselected peptides or proteins). The latter has received much attention for biomarker analysis, validation and further evaluation. However, interferences in complex biological samples often limit sensitivity in comparison with immunoassays unless appropriate sample preparation is performed [12­17]. Co-eluting peptides with a precursor ion mass close to the peptide of interest may result in fragment ions that overlap with the targeted transitions, resulting in considerable chemical noise. Such noise limits detection sensitivity and contributes to diminished accuracy and precision. However, reaching the nanograms-per-milliliter level in body fluids without using affinity binders. Measuring low protein levels (ng/mL) in trypsin-digested and fractionated serum in a reproducible manner is possible [28]. The peptides chosen ought to be unique for the protein targeted (proteotypic peptides), and the peptide must not be too short (less than 7 amino acids) or too long (more than 20 amino acids) to prevent loss of specificity and sensitivity, respectively. One should avoid ragged ends that could lead to partial enzymatic digestion and, ideally, they should contain no amino acids that are prone to chemical modifications such as oxidation. Moreover, N- and C-terminal peptides are in general more prone to degradation and should be avoided if possible. Additionally, one should be aware of protein-specific amino acid polymorphisms, posttranslational modifications. Nonetheless, unexpected modification or loss of peptides due to biological cleavage or degradation of protein subunits can introduce aberrant ratios between peptides within one protein. One is, therefore, encouraged to select at least two peptides per protein for adequate quantification. Most often, sample preparation is performed stepwise: first, lysis and denaturation; followed by reduction and alkylation of sulfhydryl groups; and finally, proteolytic (predominately tryptic) digestion. Additionally, without enrichment, both methodologies generally remain less sensitive as compared with immunoassays.

Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset back pain treatment guidelines buy motrin 400 mg lowest price. Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus treatment for nerve pain from shingles buy motrin 600 mg low price. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus rush pain treatment center meridian ms buy motrin 600 mg amex. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice pain treatment and wellness center greensburg pa purchase online motrin. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases pain medication for dogs and humans order motrin with visa. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis. Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement. Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. Quantification of proteinuria: A re-evaluation of the protein/creatinine ratio for elderly subjects. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. Random spot urine protein to creatinine ratio is a reliable measure of proteinuria in lupus nephritis in Koreans. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Utility of urinary protein-creatinine ratio and protein content in a 24-hour urine collection in systemic lupus erythematosus: A systematic review and meta-analysis. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Neutralization of interferon-alpha/betainducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Safety profile of belimumab: Pooled data from placebocontrolled phase 2 and 3 studies in patients with systemic lupus erythematosus. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Circulating follicular helper-like T cells in systemic lupus erythematosus: Association with disease activity. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus. Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Quantification of regulatory T cells in patients with systemic lupus erythematosus. Global natural regulatory T cell depletion in active systemic lupus erythematosus. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Natural regulatory T cells: Number and function are normal in the majority of patients with lupus nephritis. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Advances in Cardiovascular Diagnostics Use of Cardiac Biomarkers in Clinical Research and Care of the Patient Mark B. Biomarkers have been put forward as surrogate end points for clinical trials as they are used as diagnostic and prognostic markers of myocardial disease. In 2008, Braunwald proposed that cardiovascular biomarkers be divided into seven categories: inflammation, oxidative stress, extracellular matrix remodeling, neurohormones, myocyte injury, myocyte stress, and new biomarkers (Braunwald 2008). Although he based these categories primarily on effects in heart failure, they can apply to almost any type of cardiac disease. Recently, two different recommendations for definition of myocardial have been published and used for newer clinical trials. The first was the Universal Definition of Myocardial Infarction (Thygesen 2007), which has subsequently been revised three times, the last in 2018 (Thygesen 2018). One of the stratification factors for randomization was "baseline status" (normal or abnormal, based on a combination of biomarker levels (predominantly cardiac troponin [discussed below]), electrocardiographic changes, and symptoms. Cardiac Troponin Cardiac troponin I (cTnI) and T (cTnT) are cardiac regulatory proteins that control the calcium-mediated interaction of actin and myosin (Adams 1993). Both have early releasable and structural pools, with most troponin in the structural pool (Katus 1991, Adams 1994). These proteins are protein products of specific genes, with amino acid sequences that are cardiospecific and, therefore, have the potential to be unique for the heart. Studies performed with cTnI have failed to find any cTnI outside of the heart at any stage of neonatal development (McManus 1993). Rapid analysis for cardiac troponins has been developed and decreases the time to diagnosis in patients with chest pain (Ilva 2005, Kavsak 2007). Because of differences in the antibodies and other reagents used in the assays, numbers cannot be compared between assays and differences in numbers cannot be presumed to define sensitivity (Apple 2009). In the late 1980s, investigators developed immunoassays for troponin I and troponin T (Katus 1991, Cummins 1987). Refinements in the antibodies, reagents, and automation have made the current commercial troponin assays exquisitely sensitive and precise (Apple 2011, Bhardwaj 2011). The newest, most sensitive assays can detect troponin in the bloodstream of patients without myocardial damage, perhaps due to normal myocardial cell turnover or formation of exosomes that release small amounts of free troponin into the bloodstream (Jarolim 2015). The former is referred to as "conventional" or "sensitive" assays and the latter "high sensitivity" (hs) assays (Ilva 2005, Wu 2006, Giannitsis 2010, Venge 2009, Wilson 2009, Bhardwaj 2011). One criterion for calling an assay "hs" is the proportion of normal subjects in whom the assay is capable of detecting cTn (Apple 2012). It is now clear with hs-cTn assays that all individuals have small amounts of measurable cTn in their blood (Apple 2012). The 4th Universal Definition of Myocardial Infarction states that a stable troponin elevation pattern should be referred to as "myocardial injury" (Thysgssen 2018). In the Fourth Universal Definition of Myocardial Infarction, the presence of a typical rise and/or fall in biomarkers with 1 value above the 99th percentile of the upper reference level is the key differentiating factor of myocardial infarction. The problem seen in the clinical use of this highly diagnostic test is that cardiac troponin elevation can be present in other clinical syndromes where a myocardial infarction has not occurred. Numerous studies have shown that an increase in troponin leads to a worse prognosis (Kontos 2004, Ndrepepa 2011, Scirica 2011). This is important because it will identify a population in which more aggressive therapeutic intervention will demonstrate a risk greater than a benefit. Subsequently, clinical trials evaluating interventional therapy have been designed using an elevation in troponin in the setting of typical signs and symptoms of ischemia for entry criteria to ensure a higher risk population (Cannon 2001). They found that periprocedural elevations of cardiac troponin, unlike in studies not dependent on periprocedural infarctions, was poorly predictive of long term, and in many cases, short term outcomes. Beyond a diagnostic aid, elevated troponin levels are also shown to guide the type of therapeutic intervention such patients need. Early revascularization and intensive management benefits such patients both in short and long term outcomes (Hamm 1999, Valeur 2005, Mahmarian 2006, Desideri 2005). Troponin determination also has been shown to be associated with reduced hospital stay and charges from an administration point of view (Zarich 2001). Clinical outcome trials in the cardiovascular world usually involve a composite end point that almost always includes myocardial infarction as one of the composite end points. Interventional trials have used troponin elevation as part of the end point definition, but the rate of myocardial infarction in these studies have been fairly high (Roger 2006). Many studies, as well as the Third Universal Definition of Myocardial Infarction, have required a fall in enzyme activity associated with a subsequent rise in enzyme leakage to signify myocardial necrosis. Other Biomarkers for Diagnosing Myocardial Ischemia or Infarction Myoglobin Myoglobin is a small sized heme protein inside the cardiomyocytes and therefore it is released faster after injury occurs, with a plasma half-life of around 9 min (Isakov 1988, Klocke 1982). However, cardiac troponin is released earlier in blood than myoglobin and therefore the advantage of assessing early stage of cardiac injury obtained from myoglobin is very little. Heart failure is usually manifested by dyspnea and early fatigue and/or edema, but volume overload need not be present. Therefore, it was recognized that it would be important to have a biomarker to help with diagnosis and prognosis of the disease. Copeptin Copeptin is the C-terminal portion of the arginine vasopressin precursor peptide.

Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort pain treatment lupus 400 mg motrin order mastercard. Relationship between perceived sleep and polysomnography in older adults patients midwest pain treatment center ohio motrin 400 mg buy otc. Practice parameters for the use of the continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders pain treatment for cancer buy generic motrin 600 mg online. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea pacific pain treatment center purchase motrin 400 mg with mastercard. Adherence to continuous positive airway pressure treatment in patients with Alzheimer disease and obstructive sleep apnea pain treatment center llc order discount motrin on line. The effect of exercise training on obstructive sleep apnea and sleep quality: a randomized controlled trial. Strength training and light physical activity reduces the apneahypopnea index in institutionalized older adults. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. The effect of ambient bright light therapy on depressive symptoms in persons with dementia. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. Practice parameters for the use of light therapy in the treatment of sleep disorders. Strength training, walking and social activity improve sleep in nursing home and assisted living residents: randomized controlled trial. A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve Mindfulness meditation and improvement in sleep quality and daytime impairment among older adults with sleep disturbances: a randomized clinical trial. Self-relaxation training can improve sleep quality and cognitive functions in the older: a one-year randomised controlled trial. Mindfulness-based stress reduction for chronic insomnia in adults older than 75 years: a randomized, controlled, single-blind clinical trial. Diurnal preference, sleep habits, circadian sleep propensity and melatonin rhythm in healthy human subjects. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Melatonin for treatment of sundowning in elderly persons with dementia-a preliminary study. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. The burden of psychotropic drug prescribingin people with dementia: a population database study. Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. The association between dementia and long-term use of benzodiazepine in the elderly: nested caseÀcontrol study using claims data. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. The relationship between objectively measured sleep disturbance and dementia family caregiver distress and burden. Understanding the sleep problems of people with dementia and their family caregivers. Sleep and sleepÀwake disturbances in care recipientÀcaregiver dyads in the context of a chronic illness: a critical review of the literature. In severe cases, where critical brain areas are affected, a stroke may lead to coma or death. Although 10%À25% of stroke patients recover fully or with minor impairments,4 a vast majority of stroke survivors sustain long-term difficulties that may affect their daily life. The recovery process from stroke is modulated by several comorbid and preexisting conditions, such as heart disease,2,5 diabetes,6 age,7 or indeed sleep. The role of sleep in stroke recovery, rehabilitation, and long-term care is discussed in this chapter. Data from the Office of National Statistics report the estimated cost of stroke in the United Kingdom to be approximately d4 billion or 5. For example, stroke is now the most common cause of disability amongst young adults in India,11 and one of the leading cause of death in China. In older individuals, the prevalence of stroke seems to be higher for both men and women, respectively. Therefore, there is still a pressing need to reduce the disease burden from a social, societal, as well as economical perspective. Clinical Features In principle, there are two types of stroke, ischemic or hemorrhagic. For example, a study of 400 stroke patients and 400 controls found that the odds ratio for second stroke readmission was 3. The most effective intervention is the provision of continuous positive airway pressure which delivers a steady stream of air to the airways while the person is asleep. This is caused by a combination of the direct effects of stroke, such as loss of consciousness, pain, and the brain damage per se, as well as the treatment and medication thereof. However, there is converging evidence from subjective as well as objective measures that difficulties with sleeping remain a persistent problem in these patients. For example, questionnaire- and actigraphy-based studies report chronic sleep difficulties in 34%À67% of patients,46,47 with 48% satisfying the criteria for insomnia. Daytime electroencephalogram measures in chronic motor stroke further indicate greater prevalence of slower frequencies in resting state wake electroencephalogram,53 a phenomenon often interpreted as a marker of sleep deprivation. Either way, through stand-alone self-management approaches and/or in combination with primary interventions concerning sleep, patient benefit can be achieved. However, clinical practice in stroke rehabilitation and stroke care does not necessarily include measures for daytime sleepiness management. In addition to that, we argue that sleep is also relevant for stroke recovery, long-term outcome, and quality of life after stroke. This proposition is based on the notion that brain plasticity in terms of both, the functional and structural reorganization of neural circuits, is the key mechanism of poststroke recovery and, at the same time, is also a function of sleep. Specifically, it is now accepted that after stroke, the brain goes through stages of brain changes that, in part, represent a replication of the mechanisms at play during brain development. At the same time there is a large literature in animals and humans demonstrating the importance of sleep for memory consolidation and learning. Initial evidence for this hypothesis comes from studies suggesting that poorer sleep might lead to poorer outcome. For example, Alhola and Polo-Kantola65 reported that poor sleep negatively impacts mental and physical health, day time function, learning, and memory. In the specific case of stroke, many patients suffer from depression and are often treated with antidepressants for many years. Sleep disorders, on the other hand, are strongly associated with poor mental health and a wide range of psychiatric disorders. In essence, the model proposes that having a stroke induces physiological and psychological processes that negatively impact sleep. The psychological aspects of stroke thereby play a key role in the development and maintenance of sustained sleep disorders, in particular insomnia. Predisposing factors comprise characteristics that increase the vulnerability to sleep difficulties. Precipitating factors represent life events, medical and psychological strains that trigger insomnia. Perpetuating factors represent the psychological and behavioral elements that maintain sleep difficulties, such as changing bedtime or napping behavior, beliefs, and thoughts. This model has a clear application in the situation of stroke recovery as explained in detail in below. Many of the risk factors for stroke, such as hypertension and obesity, also increase the vulnerability to sleep difficulties and hence represent predisposing factors. The cognitive strategies and behaviors patients often have to adopt in order to cope with their condition can act as perpetuating factors. The physical and cognitive deficits induced initially by the stroke are likely to cause excessive worrying and depression which in turn may affect nocturnal sleep. We therefore argue that patients who have suffered a stroke are likely to experience insomnia in the early phase of stroke and that the prevalence of potent perpetuating factors, such as medication, may increase the risk for the development of chronic insomnia through maladaptive psychological processes and behaviors. In essence it is assumed that the stroke causes physiological changes and psychological impacts that together affect sleep, while sleep is linked to a range of factors that are important for stroke recovery. The impact of the physiological and psychological factors and their potential influence of sleep evolves and changes throughout different phases of recovery. Physiological Changes In most cases, stroke induces brain damage and is associated with an alteration in the state of consciousness, either caused directly as a result of the brain lesion or indirectly through symptom management (such as sedation or induced coma) and analgesic medication (anticoagulants, antihypertensive, antiplatelets). Poor nocturnal sleep, fatigue, and excessive daytime sleepiness are therefore very common and well documented in the acute and postacute phase of stroke. First, they may likely lead to a decrease in active participation in neurorehabilitation as well as societal participation and reintegration47,71 and also increase the risk of accidents. These psychological aspects are the immediate consequences of the life event and the dramatic change it may bring to patients and their families, as well as long-term consequences, such as coming to terms with the sustained disability. For example, patients with severe injuries to the motor cortex sustain long-term disability and may be wheelchair bound for the rest of their lives. From a sleep-recovery perspective, these patients do not only have to overcome the initial trauma of the insult but go through weeks and month of rehabilitation and recovery with the hope for a better long-term outcome, that the pain would get better, that more function would come back, and that everyday activities would become less fatiguing. As time since stroke increases, and full recovery does materialize, the psychological burden of being a stroke survivor can indeed increase, which may lead to poor nocturnal sleep. Insomnia in the Chronic Phase of Stroke Based on the above model, we conducted a series of studies in patients with moderate-to-severe hemiparesis at least 1-year poststroke using a mix of observational and descriptive studies. When asked "how is your sleep," 85% (N 5 61) reported that their sleep had persistently changed since the stroke, with the majority feeling that their sleep difficulties started in hospital. Sixty-one percent napped more since their stroke and 25% felt persistently tired or fatigued. The Pittsburgh Sleep Quality Index identified 32% of the cohort as poor sleepers; according to the Insomnia Severity Index 50, 14% of patients had insomnia (compared to 7% in the general population). Further investigations showed that the experience of poor sleep poststroke was not a simple effect of the passage of time, that is, healthy persons of a similar age do not report to have experienced dramatic changes of their sleep in the previous few years. Similar findings were obtained in a sample of younger patients with chronic low-functioning hemiparesis. Together these findings expand the literature on sleep difficulties in the earlier phases poststroke and demonstrate specifically that insomnia can continue to be a clinically relevant problem in the chronic phase poststroke, when patients had the time to adjust to their disability and are living within the community. According to the sleep-stroke recovery model, at least in some of these patients, these sleep problems represent a preventable transition from acute insomnia, initiated by the stroke event, to a chronic primary sleep disorder if early intervention was sought. A further issue to be considered is the impact of language and cognitive deficits can have on the assessment sleep difficulties. Pharmacological interventions represent the prescription of sleep promoting medications, such as benzodiazepines. However, drugbased intervention for sleep has problematic side effects and may interfere with neuroplasticity processes. Light Therapy Light therapy is used to treat sleep difficulties arising from circadian alignment of the sleepÀwake cycle, and/or depression. It can be used to entrain the body clock and the sleepÀwake pattern to the dayÀnight cycle and the socially accepted sleep times. Patients are then helped to identify and develop healthy and more effective sleep behaviors. For example, sleep restriction can initially increase tiredness and hence an increased risk of falls. To accommodate patient needs, psychoeducation components were adapted to include relevant information about stroke. When advising increased activity as part of sleep hygiene, consideration was given to the types of activity suitable for those with physical limitations. As part of stimulus control, the "15 minute" rule that requires a person to leave the bedroom should they not fall asleep within 15 minutes was felt to be too challenging for those with physical difficulties, and a relaxation routine was used instead. Sleep scheduling, which normally involves a retiming of bed/wake times and sleep restriction, was considered as an inappropriate risk to safety; therefore, "sleep compression" was used as a moderate alternative. A sleep hygiene rule of "healthy napping," which entailed napping only in bed, for no longer than 30 minutes, and not after 4 p.

Order motrin from india. slipped disc herniated disc spina disc herniation?? homeopathic medicine for slipped disc?? explain?.

References

• Willems S, Weiss C, Ventura R, et al: Catheter ablation of atrial flutter guided by electroanatomic mapping (CARTO): A randomized comparison to the conventional approach, J Cardiovasc Electrophysiol 11:1223, 2000.
• Keith M, Geranmayegan A, Sole MJ, et al: Increased oxidative stress in patients with congestive heart failure, J Am Coll Cardiol 31:1352, 1998.
• Masura J, Gavora P, Formanek A, et al. Transcatheter closure of secundum atrial septal defects using the new self centering Amplatzer septal occluder: initial human experience. Cathet Cardiovasc Diagn. 1997;42:388-93.
• Guilpain P, Servettaz A, Goulvestre C, et al: Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis, Arthritis Rheum 56(7):2455-2463, 2007.
• Morrison WH, Garden AS, Ang KK. Radiation therapy for nonmelanoma skin carcinomas. Clin Plast Surg 1997;24:719-728.
• Sen AK, Kaur M. A Comparison of screening tests for beta thalassemia trait NESTROFT v/s MOFTI and confirmation of results by ion-exchange open colum chromatography. Indian Journal of Hematology and Blood Transfusion 1998 Mar; 16(1): 31-33.